Distribution of customer contract revenue of Innovent Biologics 2022
In 2022, pharmaceutical product sales contributed the most to the customer contract revenue of Chinese pharmaceutical firm Innovent Biologics Inc., amounting to 4.14 billion yuan. The core products of Innovent Biologics include anti-tumor medicines and drugs treating metabolic disorders and autoimmune diseases.